Cerevast Therapeutics, Inc. from Redmond, Washington received CE mark approval for the Clotbust ER, a SonoLysis system used to treat ischaemic stroke in emergency settings. The device has been designed to non-invasively deliver therapeutic ultrasound energy to occluded blood vessels in the brain, together with standard intravenous thrombolytic therapy. The energy of the ultrasound beam is transformed into energy of fluid motion, also known as acoustic streaming. At very low pressures this streaming inside the brain will cause a mild “stirring” action in which additional fibrin binding sites are exposed to plasmin. This new method will enhance the clot lysis potential of conventional rtPA treatment.
Integrated software controls the delivery of consistent therapeutic levels of energy required to attain acoustic streaming, which makes the device operator independent and doesn’t require an experienced ultrasound specialist.
Cerevast Therapeutics CEO Bradford Zakes issued the following statement:
”Unlike conventional Doppler instruments that are designed and approved for diagnostic purposes only, the Clotbust ER delivers therapeutic ultrasound energy to the region of the occlusion without the need to aim the transducer or hold it in place by hand for extended periods of time. This represents a major advancement in the emergency room setting where trained sonographers or vascular technicians are not always available.”
Product page: Cerevast Therapeutics…